共 50 条
- [2] Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer [J]. BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 69 - 78
- [3] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer [J]. ONCOLOGIST, 2021, 26 : S9 - S10
- [4] Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/ HER2- metastatic breast cancer? [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1015 - 1025
- [5] Mammographic density and disease-free survival in [HR+,HER2-] locally advanced breast cancer [J]. BREAST, 2015, 24 : S103 - S103
- [6] Abemaciclib for the treatment of HR+/HER2- breast cancer [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
- [7] Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2-breast cancer: subgroup analysis of STEPAUT [J]. BREAST, 2017, 32 : S26 - S27
- [8] Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis [J]. Advances in Therapy, 2013, 30 : 870 - 884